In this issue:
Teclistamab bests physician’s choice for triple-class RRMM
Teclistamab more effective than real-world therapies in tripleclass RRMM
Ide-cel effective in real-world RRMM population
Anti-GPRC5D CAR T-cell therapy an option for RRMM
MM cell contamination in autografts confers poor outcomes
Conditional survival in myeloma and impact of prognostic factors over time
Frailty is not static and requires regular assessment
Salvage transplant improves outcomes after novel agent chemotherapy in RRMM
Increased risk of CMV infection with daratumumab
GENESIS: motixafortide + G-CSF improves stem cell mobilisation
Please login below to download this issue (PDF)